TR200200263T2 - Yeni seçiçi retinoid agonistleri - Google Patents

Yeni seçiçi retinoid agonistleri

Info

Publication number
TR200200263T2
TR200200263T2 TR2002/00263T TR200200263T TR200200263T2 TR 200200263 T2 TR200200263 T2 TR 200200263T2 TR 2002/00263 T TR2002/00263 T TR 2002/00263T TR 200200263 T TR200200263 T TR 200200263T TR 200200263 T2 TR200200263 T2 TR 200200263T2
Authority
TR
Turkey
Prior art keywords
retinoid agonists
selective retinoid
new selective
agonists
racemic
Prior art date
Application number
TR2002/00263T
Other languages
English (en)
Turkish (tr)
Inventor
Nanette Belloni Paula
Klaus Michael
Marc Lapierre Jean
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200200263T2 publication Critical patent/TR200200263T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/28—Unsaturated compounds polycyclic
    • C07C61/29—Unsaturated compounds polycyclic having a carboxyl group bound to a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/66—Polycyclic acids with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TR2002/00263T 1999-08-02 2000-07-25 Yeni seçiçi retinoid agonistleri TR200200263T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99115223 1999-08-02

Publications (1)

Publication Number Publication Date
TR200200263T2 true TR200200263T2 (tr) 2004-12-21

Family

ID=8238709

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00263T TR200200263T2 (tr) 1999-08-02 2000-07-25 Yeni seçiçi retinoid agonistleri

Country Status (18)

Country Link
US (3) US6528677B1 (enExample)
EP (1) EP1206436B1 (enExample)
JP (1) JP3961827B2 (enExample)
KR (1) KR100466730B1 (enExample)
CN (1) CN1166618C (enExample)
AR (1) AR024998A1 (enExample)
AT (1) ATE279386T1 (enExample)
AU (1) AU772551B2 (enExample)
BR (1) BR0012951A (enExample)
CA (1) CA2386793C (enExample)
DE (1) DE60014928T2 (enExample)
DK (1) DK1206436T3 (enExample)
ES (1) ES2228587T3 (enExample)
MX (1) MXPA02000828A (enExample)
PT (1) PT1206436E (enExample)
TR (1) TR200200263T2 (enExample)
WO (1) WO2001009076A2 (enExample)
ZA (1) ZA200200516B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2178B1 (en) * 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of emphysema using rar selective retinoid antagonists
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US7914437B2 (en) * 2005-02-04 2011-03-29 Ams Research Corporation Transobturator methods for installing sling to treat incontinence, and related devices
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2190429B1 (en) 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
DK2547205T3 (da) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
CA2856703A1 (en) 2011-10-19 2013-04-25 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US20160030384A1 (en) 2013-04-09 2016-02-04 Boston Biomedical, Inc. 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
DK3102576T3 (da) 2014-02-03 2019-07-22 Vitae Pharmaceuticals Llc Dihydropyrrolopyridininhibitorer af ror-gamma
SI3207043T1 (sl) 2014-10-14 2019-04-30 Vitae Pharmaceuticals, Inc. Dihidropirolopiridinovi inhibitorji za ROR-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
EP3868750A1 (en) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN115716826A (zh) 2017-07-24 2023-02-28 生命医药有限责任公司 RORγ的抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU87821A1 (fr) * 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

Also Published As

Publication number Publication date
ZA200200516B (en) 2003-06-25
AR024998A1 (es) 2002-11-06
US20030176726A1 (en) 2003-09-18
WO2001009076A3 (en) 2001-07-19
CA2386793C (en) 2006-03-28
US6528677B1 (en) 2003-03-04
US20050113447A1 (en) 2005-05-26
ES2228587T3 (es) 2005-04-16
JP2003526626A (ja) 2003-09-09
AU772551B2 (en) 2004-04-29
KR100466730B1 (ko) 2005-01-24
PT1206436E (pt) 2004-12-31
ATE279386T1 (de) 2004-10-15
EP1206436B1 (en) 2004-10-13
DK1206436T3 (da) 2005-02-14
MXPA02000828A (es) 2002-07-30
DE60014928D1 (de) 2004-11-18
KR20020030089A (ko) 2002-04-22
EP1206436A2 (en) 2002-05-22
WO2001009076A2 (en) 2001-02-08
CN1166618C (zh) 2004-09-15
CA2386793A1 (en) 2001-02-08
BR0012951A (pt) 2002-04-30
DE60014928T2 (de) 2006-03-09
US6828337B2 (en) 2004-12-07
AU6437300A (en) 2001-02-19
JP3961827B2 (ja) 2007-08-22
CN1368946A (zh) 2002-09-11

Similar Documents

Publication Publication Date Title
SE9504661D0 (sv) New compounds
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
SE9604786D0 (sv) New compounds
GB9801690D0 (en) Therapeutic agents
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
SE9900961D0 (sv) Novel compounds
CA2386793A1 (en) New selective retinoid agonists
SE9802206D0 (sv) Novel compounds
SE9802208D0 (sv) Novel compounds
ES2190647T3 (es) 2',2'-difluoronucleosidos para terapia inmunosupresora y combinaciones farmaceuticas.
SE0102055D0 (sv) New Compounds
BG102623A (bg) Нови производни на бензоилгуанидина, методи за тяхното получаване и приложението им за производството на ле- карствени средства
TR200000737T2 (tr) İkame edilmiş kroman türevleri.
BR0210912A (pt) Compostos e composições como inibidores de catepsina
DE60112960D1 (de) Kondensierte pyridoindolderivate
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
ATE253359T1 (de) Antithrombotische mittel
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
SE9802209D0 (sv) Novel compounds
SE9504662D0 (sv) New compounds
TR200001121T2 (tr) Antiromatizmal madde.
ATE286395T1 (de) Antithrombotische mittel
SE0102058D0 (sv) New Salts II